January 17, 2015
On Jan. 9, the U.S. Food and Drug Administration (FDA) approved a three-in-one test that detects HIV, hepatitis C and hepatitis B.
The test, manufactured by Roche, is the second version of the "cobas TaqScreen MPX Test." This updated version provides increased sensitivity and is the only test approved by the FDA to detect the three aforementioned viruses together.
The real-time, multi-dye PCR assay will be used to test "donations of human whole blood and blood components including source plasma," according to Roche's press release.
"The combination of viral target detection and identification steps on a fully automated system offers workflow advantages to blood and plasma testing centers by eliminating the need for consecutive rounds of testing, and facilitating earlier donor counseling in the event of a positive result," the manufacturer stated.
Warren Tong is the senior science editor for TheBody.com and TheBodyPRO.com.
Follow Warren on Twitter: @WarrenAtTheBody.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|
|'Caring at Its Essence': HIV Nurses Recall Pivotal Moments With Patients|
|PrEP Prescriptions Rise Sharply, but Unequally, in New York City|
|How to Reverse Implicit Bias in HIV Care: 6 Steps to Take Today|
|In Their Words: Burdens of HIV Nursing Include Lack of Respect and Resources|
|Conversations With Federal HIV Leaders From the 2017 U.S. Conference on AIDS|